钟磊 性别：男

2009.09-2012.06，四川大学，华西药学院，药剂学，硕士；

2012.09-2015.06，四川大学，生物治疗国家重点实验室，化学生物学，博士；

2015.07-2019.03，电子科技大学附属医院·四川省人民医院，助理研究员；

2015.10-2019.03，四川大学，生物治疗国家重点实验室，博士后（在职）；

2017.01-2021.12，电子科技大学医学院，讲师；

2019.04至今，电子科技大学附属医院·四川省人民医院，副研究员；

2022.01至今，电子科技大学医学院，副教授；

2022.05-2023.06，瑞典乌普萨拉大学，访问学者。

第二届中国药理学会治疗药物监测研究专委会青年委员会委员；

第二届四川省抗癌协会肿瘤临床药学专委会常务委员；

第二届四川省药理学学会治疗药物监测研究专委会常务委员；

第二届四川省药理学学会理事会理事。

作为项目负责人主持包括国家自然科学基金、中国博士后面上项目、四川省科技厅科研项目、四川省卫健委科研课题、成都市科技局课题，中央高校基金等在内的各级科研项目10余项。

作为项目完成人获2017年四川省医学会医学科技一等奖1项（排名12）；获2020年四川省医学会医学科技二等奖1项（排名7）。

申请发明专利4项，现已授权3项。

发表学术论文50余篇，其中，以一作或通讯作者身份发表SCI论文20余篇，IF>5分16篇，最高影响因子40.8，他引1000余次。

1. Ma Tingnan, et al. SETDB1: Progress and prospects in cancer treatment potential and inhibitor research. Bioorg Chem, 2024, 145: 107219. (通讯作者)

2. Hou Yingying, et al. Insights into vaccines for elderly individuals: from the impacts of immunosenescence to delivery strategies. NPJ Vaccines, 2024, 9 (1): 77. (并列通讯)

3. Zhong Lei, et al. Genetic differences between primary and metastatic cancer: a pan-cancer whole-genome comparison study. Signal Transduct Target Ther, 2023, 8 (1): 363.

4. Peng Haoyuan, et al. Ganoderma lucidum: Current advancements of characteristic components and experimental progress in anti-liver fibrosis. Front Pharmacol, 2023, 13: 1094405. (并列一作)

5. Lu X, Zhong L, et al. Identification of ATF3 as a novel protective signature of quiescent colorectal tumor cells. Cell Death Dis, 2023, 14 (10): 676. (并列一作)

6. Jiang Die, et al. Research progress of VEGFR small molecule inhibitors in ocular neovascular diseases. Eur J Med Chem, 2023, 257: 115535. (并列一作)

7. Peng XR, et al. Emetine, a small molecule natural product, displays potent anti-gastric cancer activity via regulation of multiple signaling pathways. Cancer Chemother Pharmacol, 2023, 91 (4): 303-315. (通讯作者)

8. Zhao ZP, et al. Role of histone methyltransferase SETDB1 in regulation of tumourigenesis and immune response. Front Pharmacol, 2022, 13: 1073713. (通讯作者)

9. Zhong Lei, et al. Recent advances in small-molecular therapeutics for COVID-19. Precision Clinical Medicine, 2022, 5: pbac024.

10. Peng XR, et al. Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges. Drug Des Devel Ther, 2022, 16: 2639-2657. (通讯作者)

11. Zhong Lei, et al. Small Molecules in Targeted Cancer Therapy: Advances, Challenges, and Future Perspectives. Signal Transduction and Targeted Therapy, 2021, 6: 201.

12. Yang ZY, et al. Discovery of BAZ1A bromodomain inhibitors with the aid of virtual screening  and activity evaluation. Bioorg Med Chem Lett, 2021,33: 127745. (通讯作者)

13. Peng XR et al. Targeting H3K36 methyltransferases NSDs: a promising strategy for tumor targeted therapy, Signal Transduction and Targeted Therapy, 2021, 6 (1): 0-220. (通讯作者)

14. Su Lingyu, et al. Anti-oral squamous cell carcinoma effects of a potent TAZ inhibitor AR-42. Journal of Cancer, 2020, 11(2): 364-373. (通讯作者)

15. Peng Qian, et al. Association of elevated Yes-associated protein expression with gastric cancer and its clinicopathological features. J Biosci Med, 2020, 8, 96-109. (通讯作者)

16. Zhong Lei, et al. Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma. Investigational New Drugs, 2019, 37: 616-624.

17. Zhou Yanping, et al. Design, synthesis and in vitro tumor cytotoxicity evaluation of 3,5-diamino-N-substituted benzamide derivatives as novel GSK-3β small molecule inhibitors. Chem. Biodiversity, 2019, 16: e1900304. (通讯作者)

18. Zhong Lei, et al. Protective effect of ethyl vanillin against Aβinduced neurotoxicity in PC12 cells via the reduction of oxidative stress and apoptosis Experimental and Therapeutic Medicine, 2019, 17: 2666-2674.

19. Zhong Lei, et al. Relevance of methylenetetrahydrofolate reductase gene variants C677T and A1298C with response to fluoropyrimidinebased chemotherapy in colorectal cancer: a systematic review and meta-analysis. Oncotarget, 2018, 9 (58): 31291-31301.

20. Yang Ling-Ling, et al. X-ray crystal structure guided discovery of new selective, substratemimicking sirtuin 2 inhibitors that exhibit activities against non-small cell lung cancer cells. European Journal of Medicinal Chemistry, 2018, 155: 806-823. (并列一作)

21. Zhong Lei, et al. Relevance of MTHFR polymorphisms with response to floropyrimidine based chemotherapy in oesophagogastric cancer: a meta-analysis. BMJ Open, 2018, 8: e020767.

22. Zhong Lei, et al. Preclinical pharmacodynamic evaluation of drug candidate SKLB-178 in the treatment of non-small cell lung cancer. Oncotarget, 2017, 8 (8): 12843-12854.  

23. Zhong Lei, et al. A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma. International Journal of Cancer, 2014, 135 (12): 2972-2983.

24. Zhong Lei, et al. A prediction model of substrates and non-substrates of breast cancer Resistance protein (BCRP) developed by GA–CG –SVM method. Computers in Biology and Medicine, 2011, 41 (11): 1006-1013.

2023年入选四川省“天府青城计划”青年科技人才计划；

2020年获批四川省卫健委学术技术带头人后备人选。